7.54
price down icon2.58%   -0.20
after-market Handel nachbörslich: 7.47 -0.07 -0.93%
loading
Schlusskurs vom Vortag:
$7.74
Offen:
$7.9
24-Stunden-Volumen:
1.40M
Relative Volume:
0.67
Marktkapitalisierung:
$463.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-2.9339
EPS:
-2.57
Netto-Cashflow:
$-67.76M
1W Leistung:
-24.68%
1M Leistung:
+36.59%
6M Leistung:
+45.00%
1J Leistung:
+125.07%
1-Tages-Spanne:
Value
$7.47
$8.05
1-Wochen-Bereich:
Value
$7.47
$10.22
52-Wochen-Spanne:
Value
$2.9106
$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name
Firmenname
Monte Rosa Therapeutics Inc
Name
Telefon
617-949-2643
Name
Adresse
321 HARRISON AVENUE, BOSTON
Name
Mitarbeiter
103
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
GLUE's Discussions on Twitter

Vergleichen Sie GLUE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
GLUE 7.54 463.23M 0 -130.41M -67.76M -2.57
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-01-03 Hochstufung Wells Fargo Equal Weight → Overweight
2022-10-13 Eingeleitet UBS Buy
2022-08-15 Eingeleitet Jefferies Buy
2022-04-28 Eingeleitet Credit Suisse Neutral
2022-02-10 Eingeleitet Wells Fargo Equal Weight
2021-10-14 Eingeleitet SVB Leerink Mkt Perform
Alle ansehen

Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten

pulisher
Nov 16, 2024

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St

Nov 12, 2024
pulisher
Nov 11, 2024

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance

Nov 11, 2024
pulisher
Nov 11, 2024

Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan

Nov 07, 2024
pulisher
Oct 31, 2024

Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 28, 2024

Novartis adds another degrader, this time from Monte Rosa - BioCentury

Oct 28, 2024
pulisher
Oct 28, 2024

This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

Boston Biotech Announces Novartis Collaboration - Streetwise Reports

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024
pulisher
Oct 28, 2024

Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals

Oct 28, 2024
pulisher
Oct 28, 2024

Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive

Oct 28, 2024
pulisher
Oct 28, 2024

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics, Inc Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Marketscreener.com

Oct 28, 2024
pulisher
Oct 28, 2024

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs - Reuters

Oct 28, 2024
pulisher
Oct 28, 2024

Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Shares Soar on Novartis Team-Up - Marketscreener.com

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa jumps on $150M license deal with Novartis (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024

Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):